Territory Hemp

One hectare of h**p produces 25 % more oxygen than one hectare of forest and guarantees a cellulose supply that is approximately twice as high.

One acre of h**p grows within 6 months, while a forest grows for decades before it is harvested.

By making h**p paper, we could save millions of hectares of forest every year.

H**p can be used in textile production, construction and even as biofuel.

Classic 🐄🤣

Eucalize legalyptus! 🙂

Australia becomes first country to recognise psychedelics as medicines

Australia becomes first country to recognise psychedelics as medicines M**A and psilocybin, the active ingredient in magic mushrooms, will be approved for controlled use for specific mental health conditions from July.

https://www.facebook.com/72924719987/posts/10163836571219988/

H**p production levels set for new highs, say farmers and academics The production of h**p in Australia has surged over the past decade. Industry experts say that could rise to a million hectares per year within the next 10 years.

ECS Botanics Holdings Ltd (ASX:ECS)
25 July 2022

Quarterly Report and Highlights for the period ending 30 June 2022

ECS recorded another record quarter with an 86% increase on the prior quarter in receipts from customers and full-year receipts up 307% from the previous year

Financial Highlights
• Quarter receipts from customers were a record $2.249 million, 86% up from the previous quarter (Q3 FY22: $1.208 million). ECS’ full year receipts were $6.006 million up 307% from the previous year (FY21: $1.475 million)

• Net cash used in operating activities of $0.782 million was a reduction of 50% from the prior quarter (Q3 FY22: $1.563 million), highlighting the value of containing operating expenses as the business grows

• During FY22 ECS invested $3.457 million in assets and infrastructure to expand capacity and a further $1.5 million in final settlement for the acquisition of Murray Meds

• After the close of the reporting period ECS secured $2 million in debt funding and entered into an agreement to sell the food and wellness business
Operational Highlights
• During the quarter ECS announced the following strategic initiatives:
o Sale of Tasmanian property and assets
o Divestment of industrial h**p Food and Wellness division
o The use of debt funding

• These initiatives are designed to focus resources on the Medicinal Cannabis sector where the Company sees the highest growth and profit trajectory whilst eliminating the operating expenses associated with the divested businesses

• During the quarter ECS exported its first shipment of Medicinal Cannabis dried flower to NUBU, New Zealand largest cannabis distributer
ECS Botanics Holdings Ltd (ASX: ECS) (“ECS” or the “Company”), a leading medicinal cannabis company, is pleased to provide the following updates on activities for the period ended 30 June 2022 (the ‘quarter’).

Management commentary:
Managing Director, Nan-Maree Schoerie said: “ECS has developed a reputation for executing on its objectives and once again we have demonstrated our ability to do what we say we are going to do, quickly, cost-effectively, and without losing focus on our deliverables. In addition to undertaking the ex*****on of the recently announced strategy, ECS has delivered another record quarter. These results reaffirm the attractiveness of our business-to-business, demand-driven model which is focused on producing low-cost, naturally grown medicinal cannabis, sustainably! A strategy which we believe also provides patients with the maximum therapeutic benefit from this natural medicine.”

About ECS Botanics
ECS Botanics Holdings Ltd is a leading medicinal cannabis business. The company’s farm and medicinal cannabis facilities are in Victoria for the cultivation, processing, and manufacturing of medicinal cannabis. ECS manufactures to EU GMP standards and also has the necessary licenses to cultivate and manufacture medicinal cannabis for the wholesale extract, final dose, and premium dry flower market. ECS’ core focus is scale and low-cost production, without compromising quality.

For further information, please contact:
Alexander Keach
Head of Corporate Relations
[email protected]

ECS Botanics Holdings Ltd (ASX:ECS)
4 July 2022

ECS Exports First Shipment to New Zealand

HIGHLIGHTS
• ECS makes the first shipment of medicinal cannabis flower to New Zealand. • ECS supplying NUBU Pharmaceuticals - New Zealand’s largest distributor of medicinal cannabis products and medical devices.

• This shipment follows the successful registration of strains in New Zealand, along with Import and Export Permits granted by authorities.

• ECS strains are the first strains to be registered for import into New Zealand as dried flower for inhalation.

• Flower to be prescribed to patients under NUBU’s brand – KIKUYA.
ECS Botanics Holdings Ltd (ASX: ECS) (“ECS” or the “Company”), a leading medicinal cannabis company, is pleased to report it has concluded its first shipment of dried cannabis flower to NUBU, New Zealand’s largest cannabis distributor. As previously announced ECS entered into a four-year supply agreement with Nubu (refer to ASX announcement: 30 August 2021). This shipment follows the successful registration of ECS Botanics strains, cultivated at the Company’s cultivation facility in Victoria. The strains are registered as flower for inhalation, the first imported cannabis flower registered for inhalation in New Zealand.

Strategic rationale – Positioning ECS for growth:
In recent years the cannabis market has evolved considerably. The number of medicinal cannabis registered doctors across Australia has increased significantly and with premium, prescription dry flower becoming a high-demand product, the market in Australia and overseas is growing rapidly. These initiatives support the ongoing focus on the medicinal cannabis (MC) division, with MC sales representing 86% of group revenue during the last quarter and growing.

NUBU’s enviable distribution network spans the length and breadth of New Zealand – encompassing every pharmacy in the country and all major specialty clinics. The company is also the leading voice in dried flower education, to prescribers and pharmacists, via NUBU’s Medical Director, Kady Chemal BPharm (Hons).

ECS anticipates that New Zealand will grow to become a strong market for ECS over the 2022/23 financial year, as the quality and competitive pricing of the Company’s GMP-certified naturally, and organically grown products become increasingly in demand.

The company is currently progressing product registration in Poland and Germany.

Managing Director of ECS, Nan-Maree Schoerie said: “This shipment demonstrates ECS’ high-quality products, as New Zealand has one of the highest barriers for entry for imported medicinal cannabis. At ECS we proudly grow our cannabis naturally in soil. This ensures our flowers contain the full spectrum of primary and secondary metabolites for maximum therapeutic benefit. I am confident that our product will be as well received by New Zealand patients, as it has been by our Australian and other overseas patients.”

GMP licence issued for Mildura facility
In combination with the licences and permits issued by the Office of Drug Control (ODC) earlier this year, the GMP licence will allow us to produce active pharmaceutical ingredients (APIs) at the facility, manufacture Satipharm capsules for human therapeutic use, and perform in-house chemical, physical, and microbiological tests to demonstrate that products meet local and overseas regulatory requirements.
This is the final piece of the regulatory puzzle for Mildura, which is now able to cultivate, extract, manufacture, test, and supply a wide range of medicinal cannabis products for patients entirely in-house.
Coming off the back of Mildura’s first commercial harvest of medicinal cannabis crops earlier in June, this has been one of the most significant months in the history of the company. We would like to acknowledge the hard work of the Cann Group teams who made this happen, and the support we continue to receive from our investors and strategic partners.

1st Photo: Our Mildura facility has just been granted a GMP licence by the TGA.

2nd Photo: our patented microspheres, used in our Satipharm CBD capsules, in production in one of our GMP suites at our Mildura facility

W**d Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021

W**d Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021 - Stockhead ROO receives USA design patent approval for its Heat Exchange Probe and EMD has launched its second ultra-pure CBD capsule, the EMD-RX7.

Yep, cannabis and horses 🤣

Is there anything cannabis doesn't cure?

W**d Week: Cannabis compounds could prevent Covid and Quebec’s no-jab, no-weed rule quadruples vaccinations

https://stockhead.com.au/health/weed-week-cannabis-compounds-could-prevent-covid-and-quebecs-no-jab-no-weed-rule-quadruples-vaccinations/?utm_medium=email&utm_campaign=Stockhead%20Morning%20Newsletter-01-13-2022&utm_content=httpsstockheadcomauhealthweedweekcannabiscompoundscouldpreventcovidandquebecsnojabnoweedrulequadruplesvaccinations&utm_medium=email&utm_campaign=Morning%20email%20Friday%20January%2014&utm_content=Morning%20email%20Friday%20January%2014+CID_d9b3eb268990cc096550498e0d19ca5e&utm_source=Campaign%20Monitor&utm_term=W**d%20Week%20Cannabis%20compounds%20could%20prevent%20Covid%20and%20Quebecs%20no-jab%20no-weed%20rule%20quadruples%20vaccinations

(Pic: janiecbors (E+) via Getty Images)

W**d Week: Cannabis compounds could prevent Covid and Quebec's no-jab, no-weed rule quadruples vaccinations - Stockhead ECS Botanics (ASX:ECS) expects to record revenue for Q2 FY22 of $1.5 million – a 325% increase on the previous corresponding period.

Who would've thought? 🙂

Creso Pharma’s subsidiary Halucenex’s key psychedelic ingredient passes crucial testing and is one step closer to phase two clinical trials

Creso Pharma’s subsidiary Halucenex’s key psychedelic ingredient passes crucial testing and is one step closer to phase two clinical trials - Stockhead In a major step towards a Phase II clinical trial Halucenex has received favourable results from stability testing for its GMP grade psilocybin.

Incannex Healthcare (IHL:ASX) is developing a unique psilocybin therapy for the treatment of generalised anxiety disorder (GAD). Image: Getty

IHL’s psilocybin treatment takes 2 steps forward, with a boost from the FDA and ethics approval to commence trials at Monash University

IHL’s psilocybin treatment takes 2 steps forward, with a boost from the FDA and ethics approval to commence trials at Monash University - Stockhead Incannex Healthcare (ASX:IHL) is developing a unique psilocybin therapy for the treatment of generalised anxiety disorder (GAD).

Creso Pharma on track for Phase 2 trial of psilocybin, as TGA releases a new report on psychedelics.

Creso Pharma on track for Phase 2 trial of psilocybin, as TGA releases a new report on psychedelics - Stockhead The independent report by the TGA could potentially open the door for Creso Pharma to capture the Australian market as a first mover.

MGC Pharma receives first order in the US, as it seeks to fast track commercialisation of CimetrA

MGC Pharma receives first order in the US, as it seeks to fast track commercialisation of CimetrA - Stockhead Europe-based biotech MGC Pharma (ASX:MXC) has made crucial progress in its effort to fast track the sale of CimetrA in the US.

CBD Oil: The ultimate investor’s guide to a potential $64 billion global market

CBD Oil: The ultimate investor's guide to a potential $64 billion global market - Stockhead Here's all you need to know about CBD oil. How it's extracted and what are sold in the market. We also talk about ASX cannabis stocks that are launching

In Canada, cannabis is as big as autos… and these ASX stocks are in for the ride

In Canada, cannabis is as big as autos... and these ASX stocks are in for the ride - Stockhead For as long as Australia's cannabis industry has existed, companies have looked to Canada with hope for what Australia's industry could be.

Creso Pharma completes acquisition of Canada-based Halucenex, set to enter the US$100 billion psychedelic market

Creso Pharma completes acquisition of Canada-based Halucenex, set to enter the US$100 billion psychedelic market - Stockhead The completion of Creso Pharma’s acquisition of Halucenex is set to unlock a number of lucrative opportunities in psychedelic medicines.

Finally in July 2021, a long 4.5 years after legalisation, Tasmanian GP's can prescribe medicinal cannabis AND under Tasmanian law, unimpaired Medical Cannabis patients can drive.

Any Tasmanian GP can prescribe cannabis - 7 Nightly News As of July 1 all GP's in Tasmania can prescribe medicinal cannabis products.Tasmania was the only jurisdiction in Australia where GPs could not prescribe med...

Creso Pharma delivers another strong quarter as Connecticut brings a new market opportunity

Creso Pharma delivers another strong quarter as Connecticut brings a new market opportunity - Stockhead Creso delivers strong consecutive quarters, as it gears up to scale up the North American business following the potential merger with Red Light Holland.

Here’s why the Althea (ASX:AGH) share price is racing higher today

Here's why the Althea (ASX:AGH) share price is racing higher today The Althea Group Holdings Ltd (ASX:AGH) share price is racing higher today following a positive announcement...

Small Caps ASX Australian stock market
Little Green Pharma accelerates medicinal cannabis growth plans with purchase of Danish manufacturing facility

Little Green Pharma accelerates medicinal cannabis growth plans with purchase of Danish manufacturing facility Perth-based medicinal cannabis producer Little Green Pharma (ASX: LGP) has accelerated its global growth plans with the $21.48 million acquisition of a cultivation facility in Denmark owned by Canada’s Canopy Growth Corporation.

Gina Rinehart’s Hancock Prospecting made a $15 million investment into cannabis cultivator Little Green Pharma

Gina Rinehart's Hancock Prospecting made a $15 million investment into cannabis cultivator Little Green Pharma - Stockhead Hancock Prospecting, Gina Rinehart's mining company, made an investment of $15 million into cannabis stock Little Green Pharma (ASX:LGP).